Synopsis: The US FDA has approved Gilead Sciences’ lenacapavir, a twice-yearly injectable drug branded as Yeztugo, for HIV prevention in adults and adolescents. The landmark approval brings new hope in curbing the 44-year-old HIV epidemic.
Revolution in HIV Prevention: Yeztugo Approved
In a breakthrough for HIV prevention, the U.S. Food and Drug Administration (FDA) has granted approval to Gilead Sciences’ lenacapavir, a twice-yearly pre-exposure prophylaxis (PrEP) injection, under the brand name Yeztugo. This new capsid inhibitor has shown nearly 100% effectiveness in clinical trials and is expected to revolutionize the prevention of HIV transmission.
Lenacapavir is the first long-acting, biannual injectable HIV prevention drug, offering a game-changing alternative to daily oral PrEP. This approval is seen as a pivotal moment in the fight against HIV, which still infects 1.3 million people globally each year.
The Science journal named lenacapavir the “2024 Breakthrough of the Year,” reflecting its global health potential. Gilead plans an aggressive rollout in the U.S. and intends to expand access globally in partnership with health organizations and governments.
Gilead Speaks
"This is a milestone moment,” said CEO Daniel O’Day. “Lenacapavir is the most important tool we have yet to bend the arc of the HIV epidemic and move it into the history books.”
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Please consult qualified healthcare professionals before making any medical or treatment decisions.
